医学
卵巢癌
肿瘤科
内科学
贝伐单抗
化疗
癌症
重症监护医学
作者
Debra L. Richardson,Ramez N. Eskander,David M. O’Malley
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2023-04-20
卷期号:9 (6): 851-851
被引量:104
标识
DOI:10.1001/jamaoncol.2023.0197
摘要
Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during the disease course. Outcomes for patients with platinum-resistant ovarian cancer are poor, and options remain limited, highlighting a substantial unmet need for new treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI